Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Financial Crisis? Australian Biotech Enters Golden Era (Part 2 of 2)

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - As Australia's biotech sector comes of age, it is beginning to attract the attention of multinational companies, as evidenced by stepped-up merger and acquisition activity and rounds of new funding in the last six months

You may also be interested in...



Australia Ramps Up Early Research Via Medical Research Commercialization Fund

Funding for early-stage research has been a huge problem in Australia until recently, and new funding mechanisms have come just in time as research begun a decade ago moves into development.

Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund

PERTH, Australia - Eli Lilly and the Queensland government have formed a $250 million venture capital fund to invest in Australia's biotech sector, Queensland Premier Anna Bligh announced May 20

Lilly And Queensland Government Invest In First-ever Australian Biotech VC Fund

PERTH, Australia - Eli Lilly and the Queensland government have formed a $250 million venture capital fund to invest in Australia's biotech sector, Queensland Premier Anna Bligh announced May 20

Related Content

UsernamePublicRestriction

Register

SC074012

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel